These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 21833000

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T, Fujimoto A, Nakao K, Saruta T, CASE-J Trial Group.
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [Abstract] [Full Text] [Related]

  • 4. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [Abstract] [Full Text] [Related]

  • 5. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T, CASE-J Trial Group.
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [Abstract] [Full Text] [Related]

  • 6. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
    Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K, CASE-J Study Group.
    Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
    [Abstract] [Full Text] [Related]

  • 7. [Clinical implications from the results of the CASE-J extension].
    Yasuno S, Fujimoto A, Ueshima K.
    Nihon Rinsho; 2012 Mar; 70(3):519-27. PubMed ID: 22514936
    [Abstract] [Full Text] [Related]

  • 8. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 10. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J, Hagiwara N, Ogawa H, Koyanagi R, Kasanuki H, Takagi A, Mori F, Nagashima M, Yagi M, HIJ-CREATE Investigators.
    Am J Cardiol; 2010 Sep 15; 106(6):819-24. PubMed ID: 20816122
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
    Liu J, Yasuno S, Oba K, Konda M, Ichihara C, Kitao H, Kuwabara Y, Ueshima K.
    J Hypertens; 2018 Sep 15; 36(9):1921-1928. PubMed ID: 29750680
    [Abstract] [Full Text] [Related]

  • 12. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G, Schmieder R, Calvo C, Asmar R.
    Am J Hypertens; 2006 Jan 15; 19(1):113-21. PubMed ID: 16461202
    [Abstract] [Full Text] [Related]

  • 13. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group.
    Lancet; 2004 Jun 19; 363(9426):2022-31. PubMed ID: 15207952
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II Investigators.
    Europace; 2011 Apr 19; 13(4):473-9. PubMed ID: 21148662
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr 19; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R, Hagiwara N, Yamaguchi J, Kawada-Watanabe E, Haruta S, Takagi A, Ogawa H, HIJ-CREATE Investigators.
    J Cardiol; 2013 Oct 19; 62(4):217-23. PubMed ID: 23778009
    [Abstract] [Full Text] [Related]

  • 17. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan.
    Ogihara T, Matsuoka H, Rakugi H.
    Geriatr Gerontol Int; 2011 Oct 19; 11(4):414-21. PubMed ID: 21410854
    [Abstract] [Full Text] [Related]

  • 18. [CASE-J].
    Fukui T.
    Nihon Rinsho; 2006 Aug 19; 64 Suppl 6():449-53. PubMed ID: 16981578
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R, Mugellini A, Derosa G, CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group.
    J Renin Angiotensin Aldosterone Syst; 2007 Sep 19; 8(3):139-44. PubMed ID: 17907102
    [Abstract] [Full Text] [Related]

  • 20. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.
    Nephron Clin Pract; 2005 Sep 19; 99(1):c18-23. PubMed ID: 15637459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.